Prevalence of Cardioprotective Medication Use in Coronary Heart Disease Patients in South America: Systematic review and Meta-Analysis
References
- Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Compare [Internet]. GBD Compare Data Visualization; 201AD.
http://www.healthdata.org/gbd/2019 (accessed 9 June 2021). - Gaedke MA, Soares Dias da Costa J, Fernandes Manenti E, et al. Use of medicines recommended for secondary prevention of acute coronary syndrome. Rev Saúde Púbilca. 2015; 49(88). DOI: 10.1590/S0034-8910.2015049005978
- Berwanger O, Alberto L, Fernando J, et al. Special Article Evidence-Based Therapy Prescription in High-Cardiovascular Risk Patients: The REACT Study. Arq Bras Cardiol. 2013; 100(3): 212–20. DOI: 10.5935/abc.20130062
- Ergatoudes C, Thunström E, Rosengren A, et al. Long-term secondary prevention of acute myocardial infarction (SEPAT) – guidelines adherence and outcome. BMC Cardiovasc Disord [Internet]. 2016; 16(1): 1–8. DOI: 10.1186/s12872-016-0400-6
- Herdy AH, López-Jiménez F, Terzic CP, et al. South american guidelines for cardiovascular disease prevention and rehabilitation. Arq Bras Cardiol. 2014; 103(2): 1–31. DOI: 10.5935/abc.2014S003
- Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing Epidemic of Coronary Heart Disease in Low- and Middle-Income Countries. Curr Probl Cardiol. 2010; 35(2): 72–115. DOI: 10.1016/j.cpcardiol.2009.10.002
- Perel P, Avezum A, Huffman M, et al. Reducing Premature Cardiovascular Morbidity and Mortality in People With Atherosclerotic Vascular Disease The World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease. Glob Heart. 2015; 10(2): 99–110. DOI: 10.1016/j.gheart.2015.04.003
- Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): A prospective epidemiological survey. Lancet. 2011; 378(9798): 1231–43. DOI: 10.1016/S0140-6736(11)61215-4
- Naderi SH, Bestwick JP, Wald DS. Adherence to Drugs That Prevent Cardiovascular Disease: Meta-analysis on 376,162 Patients. AJM. 2012; 125(9): 882–887.e1. DOI: 10.1016/j.amjmed.2011.12.013
- Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. Cardiovascular prevention guidelines in daily practice: A comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009; 373(9667): 929–40. DOI: 10.1016/S0140-6736(09)60330-5
- Maddox TM, Chan PS, Spertus JA, et al. Variations in coronary artery disease secondary prevention prescriptions among outpatient cardiology practices: Insights from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol. 2014; 63(6): 539–46. DOI: 10.1016/j.jacc.2013.09.053
- Avezum A, Oliveira GBF, Lanas F, et al. Secondary CV Prevention in South America in a Community Setting: The PURE Study. Glob Heart. 2017; 12(4): 305–13. DOI: 10.1016/j.gheart.2016.06.001
- Zhao M, Klipstein-grobusch K, Wang X, et al. Prevalence of cardiovascular medication on secondary prevention after myocardial infarction in China between 1995–2015: A systematic review and meta-analysis. PLoS ONE. 2017; Ci: 1–16. DOI: 10.1371/journal.pone.0175947
- Zhao M, Cooney MT, Klipstein-Grobusch K, et al. Simplifying the audit of risk factor recording and control: A report from an international study in 11 countries. Eur J Prev Cardiol. 2016; 23(11): 1202–10. DOI: 10.1177/2047487316647827
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62(10): 1006–12. DOI: 10.1016/j.jclinepi.2009.06.005
- Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan — a web and mobile app for systematic reviews. Systematic Reviews; 2016. DOI: 10.1186/s13643-016-0384-4
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez NJGC. Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009; 42(2): 377–81. DOI: 10.1016/j.jbi.2008.08.010
- Li H, Oldenburg B, Chamberlain C, et al. Diabetes prevalence and determinants in adults in China mainland from 2000 to 2010: A systematic review. Diabetes Res Clin Pract. 2012; 98(2): 226–35. DOI: 10.1016/j.diabres.2012.05.010
- RStudio Team.
RStudio: Integrated Development Environment for R . Boston, MA: RStudio, Inc.; 2016. - Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010; 36(3): 1–48. DOI: 10.18637/jss.v036.i03
- Ribeiro D, Silva RP, Barboza DRMM, Lima-Júnior RCP, Ribeiro RA. Clinical correlation between N-terminal pro-b-type natriuretic peptide and angiographic coronary ather-osclerosis. Clinics. 2014; 69(6): 405–12. DOI: 10.6061/clinics/2014(06)07
- Finimundi HC, Caramori PA, Parker JD. Effect of Diuretic Therapy on Exercise Capacity in Patients With Chronic Angina and Preserved Left Ventricular Function. 2007; 49(5): 275–9. DOI: 10.1097/FJC.0b013e3180385ad7
- Hueb W, Soares P, Gersh B, et al. The Medicine, Angioplasty, or Surgery Study (MASS-II): A Randomized, Controlled Clinical Trial of Three Therapeutic Strategies for Multivessel Coronary Artery Disease. J Am Coll Cardiol. 2004; 43(10). DOI: 10.1016/j.jacc.2003.08.065
- Scherr C, Cunha AB da, Magalhães CK, Abitibol RA, Barros M, Cordovil I. Life-habit intervention in a public institution. Arq Bras Cardiol. 2010; 94(6): 730–7. DOI: 10.1590/S0066-782X2010005000058
- Silveira AD, Ribeiro RA, Rossini APW, et al. Association of anemia with clinical outcomes in stable coronary artery disease. Pathophysiol Nat Hist. 2005; 19(1): 21–6. DOI: 10.1097/MCA.0b013e3282f27c0a
- Gomes VO, Blaya P, Lasevitch R, et al. Original Article Impact of Chronic Kidney Disease on the Efficacy of Drug-Eluting Stent: Long-term Follow-up Study. Arq Bras Cardiol. 2011; 96(5): 346–51. DOI: 10.1590/S0066-782X2011005000045
- Villacorta AS, Junior HV, Batista MJS, et al. Original Article High On-Treatment Platelet Reactivity Predicts Cardiac Events in Patients with Drug-Eluting Stents. Arq Bras Cardiol. 2013; 100(3): 221–7. DOI: 10.5935/abc.20130044
- Pesaro AEP, Serrano CV, Fernandes JL, et al. Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin. Int J Cardiol. 2012; 158(3): 400–4. DOI: 10.1016/j.ijcard.2011.01.062
- Santos VF, Braga F, Almeida Junior GLG, et al. Resistência ao AAS na doença coronariana estável. Int j Cardiovasc Sci. 2015; 28(5): 363–9.
- Kimura-medorima ST, Paula A, Lazaro B, et al. P-wave duration is a predictor for long-term mortality in post-CABG patients. 2018; 1–13. DOI: 10.1371/journal.pone.0199718
- Breda JR, Silvia A, Ragognetti C, et al. Effect of ventral cardiac denervation in the incidence of atrial fibrilation after coronary artery bypass graft surgery. 2008; 23(2): 204–8.
- Ribeiro MS, Nascimento TCDC, Murakami B, Bergamasco EC, Lopes CT, Santos ER. Desfechos clínicos dos pacientes submetidos à intervenção coronária percutânea com stent bioabsorvível eluidor de everolimus. Medicina (B Aires). 2018; 51(4): 237–46. DOI: 10.11606/issn.2176-7262.v51i4p237-246
- Saffi MAL, Polanczyk CA, Rabelo-Silva ER. Lifestyle interventions reduce cardiovascular risk in patients with coronary artery disease: A randomized clinical trial. Eur J Cardiovasc Nurs. 2014; 13(5): 436–43. DOI: 10.1177/1474515113505396
- Souza CF, El Mouallem AM, de Brito Júnior FS, Abizaid AA, Almeida BO, Almeida AG, Nascimento TC, Perin MA, Caixeta A. Safety and efficacy of biolimus-eluting stent with biodegradable polymer: insights from EINSTEIN (Evaluation of Next-generation drug-eluting STEnt IN patients with coronary artery disease) Registry. Einstein (Sao Paulo). 2013 Jul–Sep; 11(3): 350–6. DOI: 10.1590/s1679-45082013000300015. PMID: 24136763; PMCID: PMC4878595.
- Vilar CP, Cotrim HP, Florentino GSA, Bragagnoli G, Schwingel PA, Barreto CPV. Doença hepática gordurosa não alcoólica em pacientes com doença coronariana de uma área do nordeste do Brazil. Arq Gastroenterol. 2015; 52(2): 111–6. DOI: 10.1590/S0004-28032015000200007
- Nery RM, Zanini M, Lima B De, Bühler P. Tai Chi Chuan improves functional capacity after myocardial infarction: A randomized clinical trial. Am Heart J. 2015; 169(6): 854–60. DOI: 10.1016/j.ahj.2015.01.017
- Liberato ACS, Rodrigues RCM, São-João TM, Costa Alexandre NM, Bueno Jayme Gallani MC. Satisfaction with medication in coronary disease treatment: Psychometrics of the Treatment Satisfaction Questionnaire for Medication. Rev Latino-Am Enfermagen. 2016; 24:
e2705 . DOI: 10.1590/1518-8345.0745.2705 - Mattos LA, Berwanger O, Silva E, et al. Clinical Outcomes at 30 days in the Brazilian Registry of Acute Coronary Syndromes (ACCEPT). Arquivos Brasileiros de Cardiologia. 2012; 100(1): 6–13.
- Furuya RK, Arantes EC, Dessotte CAM, et al. Randomized controlled trial of an educational programme to improve self-care in Brazilian patients following percutaneous coronary intervention. John Wiley Sons Ltd. 2014; 895–908. DOI: 10.1111/jan.12568
- de Oliveira LMSM, Costa IMNB de C, da Silva DG, et al. Readmission of patients with acute coronary syndrome and determinants. Arq Bras Cardiol. 2019; 113(1): 42–9. DOI: 10.5935/abc.20190104
- Simon S, Coronel C, Silveira de Almeida A, Marcadenti A. Left lateral intercostal region versus subxiphoid position for pleural drain during elective coronary artery bypass graft surgery: Randomized clinical trial. Sao Paulo Med J. 2019; 137(1): 66–74. DOI: 10.1590/1516-3180.2018.040940119
- Chaves GSS, Lima G, Ghisi DM, Britto RR, Grace SL. Maintenance of Gains, Morbidity, and Mortality at 1 Year Following Cardiac Rehabilitation in a Middle-Income Country: A Wait-List Control Crossover Trial. J Am Heart Assoc. 2019; 8:
e011228 . DOI: 10.1161/JAHA.118.011228 - Carvalho T De, Curi ALH, Andrade DF, Singer J da M, Benetti M, Mansur AJ. Cardiovascular Rehabilitation of Patients With Ischemic Heart Disease Undergoing Medical Treatment, Percutaneous Transluminal Coronary Angioplasty, and Coronary Artery Bypass Grafting. Arq Bras Cardiol. 2006; 88(1): 65–70.
- Uchôa CHG, De Jesus Danzi-Soares N, Nunes FS, et al. Impact of OSA on cardiovascular events after coronary artery bypass surgery. Chest. 2015; 147(5): 1352–60. DOI: 10.1378/chest.14-2152
- Lima-Filho GL, Foss MC. Predictors of restenosis after percutaneous coronary intervention using bare-metal stents. A comparison between patients with and without dysglycemia Predictors of restenosis after percutaneous coronary intervention using bare-metal stents. A comparison. Braz J Med Biol Res. 2010; 43(6): 572–9. DOI: 10.1590/S0100-879X2010007500051
- Cruz LN, Camey SA, Fleck MP, Polanczyk CA. World Health Organization quality of life instrument-brief and Short Form-36 in patients with coronary artery disease: Do they measure similar quality of life concepts? Psychol Heal Med. 2009; 14(5): 619–28. DOI: 10.1080/13548500903111814
- Pantoni F, Caruso R, Mezzalira D, Arena R, Amaral-Neto O. Continuous Positive Airway Pressure During Exercise Improves Walking Time in Patients Undergoing Inpatient Cardiac Rehabilitation After Coronary Artery Bypass Graft Surgery. J Cardiopulm Rehabil Prev. 2016; 36: 20–7. DOI: 10.1097/HCR.0000000000000144
- Birk MG, Carvalho Goulart A, Lotufo PA, Martins Benseñor I. Secondary prevention of coronary heart disease: A cross-sectional analysis on the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Sao Paulo Med J. 2019; 137(3): 223–33. DOI: 10.1590/1516-3180.2018.0531140319
- Lorenzo A De, Oliveira G, Naue VM, Lima RSL. Influence of typical angina versus inducible myocardial ischemia in the contemporary management of stable coronary artery disease. Ther Adv Cardiovasc Dis. 2014; 8(4): 145–54. DOI: 10.1177/1753944714531066
- Bohatch Júnior MS, Matkovski PD, Di Giovanni FJ, Fenili R, Varella EL, Dietrich A. Incidence of postoperative atrial fibrillation in patients undergoing on-pump and off-pump coronary artery bypass grafting. Braz J Cardiovasc Srug. 2015; 30(3): 316–24. DOI: 10.5935/1678-9741.20150040
- Feguri GR, Ruiz P, Lima L De, Borges DDC, Toledo LR. Preoperative carbohydrate load and intraoperatively infused omega-3 polyunsaturated fatty acids positively impact nosocomial morbidity after coronary artery bypass grafting: A double- blind controlled randomized trial. Nutr J. 2017; 16(24): 1–7. DOI: 10.1186/s12937-017-0245-6
- Garlet AB, Machado Cardoso D, Daros dos Santos T, Nunes Pereira S. Relationship between functional class and left ventricular ejection fraction in patients with coronary heart disease candidates for cardiac rehabilitation. Sci Med. 2017; 27(3).
- Lelis JD, Chaves G, Lima G, Ghisi DM, Grace SL, Britto RR. Validity of the Incremental Shuttle Walk Test to Assess Exercise Safety When Initiating Cardiac Rehabilitation in Low-Resource Settings. J Cardiopulm Rehabil Prev. 2019; 99(April 2017): E1–7. DOI: 10.1097/HCR.0000000000000412
- Alexandre A, Aguiar F De, Mourilhe-rocha R, Esporcatte R, Amorim LC. Original Article Long-Term Analysis in Acute Coronary Syndrome: Are there any Differences in Morbidity and Mortality? 2010; 705–12.
- Fernandes RWA, Dantas JM, et al. Original Article Impact of Stenting and Oral Sirolimus on Endothelium-Dependent and Independent Coronary Vasomotion. Arquivos brasileiros de cardiologia. 2011; 290–9.
- Fuchs ARCN, Meneghelo RS, Stefanini E, et al. Exercise may cause myocardial ischemia at the anaerobic threshold in cardiac rehabilitation programs. Brazilian Journal of Medical and Biological Research. 2009; 42: 272–8. DOI: 10.1590/S0100-879X2009000300008
- Abreu-Silva EO, Costa RA, Abizaid AS, et al. Stents Farmacológicos Liberadores de Everolimus XienceTM V no Tratamento de Pacientes com Lesões Coronárias Complexas na Prática Diária: Resultados Iniciais do Registro Brasileiro BRAVO. Rev Bras Cardiol Invasiva. 2011; 19(4): 357–66. DOI: 10.1590/S2179-83972011000400005
- Baptista VC, Palhares LC, Paulo P, et al. Six-minute walk test as a tool for assessing the quality of life in patients undergoing coronary artery bypass grafting surgery. Revista Brasileira de Cirurgia Cardiovascular. 2012; 27(2): 231–9. DOI: 10.5935/1678-9741.20120039
- Rossi E, Perman G, Michelangelo H, et al. Adherencia a la prevención secundaria de la enfermedad coronaria. Med (Buenos Aires). 2014; 74: 99–103.
- Trivi M, Lakowsky A, Zeballos C, et al. Registro prospectivo de tratamiento antitrombótico en síndromes coronarios agudos (EPICOR) Prospective Registry of Antithrombotic Therapy in Acute Coronary Syndromes (EPICOR). Rev Argent Cardiol. 2019; 87(1).
- Siniawski D, Masson W, Rossi E, Damonte J, Halsband A, Pizarro R. Elegibilidad para la indicación de inhibidores de PCSK9 según las recomendaciones de diferentes sociedades científicas. Med. 2019; 79(2): 104–10.
- Alvarez J, Migliaro G, Leiva G, et al. Angioplastia primaria en diabéticos vs. no diabéticos con infarto agudo de miocardio: predictores de mortalidad. Rev Gastroenterol México. 2016; 86(1): 11–7. DOI: 10.1016/j.acmx.2015.08.006
- Gurfinkel EP, Leon R, Fuente D, Mendiz O. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study One-year follow-up. Eur Heart J. 2004; 25: 25–31. DOI: 10.1016/j.ehj.2003.10.018
- Castillo Costa YB, Mauro VM, Charask AA, Fairman E, Buhezo H, Barrero C. Use of high-intensity statin strategy. Are the guidelines followed? Rev Argent Cardiol. 2018; 86(1): 45–7. DOI: 10.7775/rac.v86.i1.11430
- Stockins B, Albornoz F, Martínez D, et al. Resultados chilenos del registro intenacional de factores de riesgo y tratamiento de angina inestable e infarto al miocardio sin supradesnivel del segmento ST: ACCORD (ACcute CORonary syndrome Descriptive study). Rev Med Chile. 2011; 139: 19–26. DOI: 10.4067/S0034-98872011000100003
- Nazzal A, Mercadal E, Garcés E, Yovaniniz P, Sanhueza P. Prevención secundaria post infarto agudo de miocardio en hospitales públicos: implementación y resultados de las garantías GES. Rev Med Chile. 2013; 141: 977–86. DOI: 10.4067/S0034-98872013000800003
- Neira VV, Potthoff MN, Quiñiñir LS, et al. Logro de metas de prevención secundaria, prescripción farmacológica y eventos cardiovasculares mayores en pacientes con enfermedad coronaria. Rev Med Chile. 2013; 141: 870–8. DOI: 10.4067/S0034-98872013000700006
- Noriega V, Pennanen C, Sánchez MP, et al. (TTA)n Polymorphism in 3-Hydroxy-3-Methylglutaryl-Coenzyme A and Response to Atorvastatin in Coronary Artery Disease Patients. Basic Clin Pharmacol Toxicol. 2008; 104: 211–5. DOI: 10.1111/j.1742-7843.2008.00341.x
- Fernandez A, Restrepo R, Villa P, Garcés J, Montero G. Angioplasty with stent vs. coronary artery bypass grafting in multivessel disease (ACIRE). Colomb J Cardiol. 2009; 16(2).
- Fernandez A, Aboodi MS, Milewski K, Delgado JA, Rodríguez A, Granada JF. Comparison of Adverse Cardiovascular Events and Bleeding Complications of Loading Dose of Clopidogrel 300 mg Versus 600 mg in Stable Patients Undergoing Elective Percutaneous Intervention (from the CADICE Study). AJC. 2011; 107(1): 6–9. DOI: 10.1016/j.amjcard.2010.08.035
- Rueda-Clausen CF, Lahera V, Calderón J, et al. The presence of abdominal obesity is associated with changes in vascular function independently of other cardiovascular risk factors. Int J Cardiol. 2010; 139(1): 32–41. DOI: 10.1016/j.ijcard.2008.09.005
- Vesga BE, Echeverri D. Resistencia al ácido acetil salicílico en pacientes con enfermedad coronaria. Rev Colomb Cardiol. 2006; 13(1): 13–22.
- Gambogi RA, Baldizzoni M, Albornoz H, et al. Prevención secundaria en pacientes revascularizados coronarios en Uruguay: descripción de un programa, evaluación del control de los factores de riesgo y efecto en la mortalidad. Clin Invest Ateriosc. 2010; 22(2): 59–69. DOI: 10.1016/j.arteri.2009.12.001
- Dayan V, Perez D, Silva E, Soca G, Estigarribia J. CABG and preoperative use of beta-blockers in patients with stable angina are associated with better cardiovascular survival. Brazilian J Cardiovasc Surg. 2018; 33(1): 47–53. DOI: 10.21470/1678-9741-2017-0138
- Vazquez H, Burdiat G, Alonso P, Sandoya E, Tejada J. Control del riesgo cardiovascular postinternación en pacientes coronarios. Rev Urug Cardiol. 2011; 26: 108–14.
- de Souza Groia Veloso RC, Cruzeiro M, Menezes Dias B, Moreira Reis AM. Profile of use and access to statins in patients with coronary arterial disease in an outpatient clinic of a teaching hospital. Curr Med Res Opin. 2020; 36(9): 1427–31. DOI: 10.1080/03007995.2020.1793313
- Mendis S, Abegunde D, Yusuf S, Ebrahim S, Shaper G, Ghannem H. WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ. 2005; 83(11): 820–31.
- Castro LT De, Santos IDS, Goulart AC, et al. Elevated High-Sensitivity Troponin I in the Stabilized Phase after an Acute Coronary Syndrome Predicts All-Cause and Cardiovascular Mortality in a Highly Admixed Population: A 7-Year Cohort. Arq Bras Cardiol. 2019; 112(3): 230–7. DOI: 10.5935/abc.20180268
- Henrique L, Gowdak W, Arantes RL, et al. Underuse of American College of Cardiology/American Heart Association Guidelines in Hemodialysis Patients Underuse of American College of Cardiology/American Heart Association Guidelines in Hemodialysis Patients. Ren Fail. 2009; 29: 559–65. DOI: 10.1080/08860220701395002
- Ogawa Indio do Brasil C, Avezum Á, Uint L, et al. Cardiovascular prevention in coronary heart disease patients: Guidelines implementation in clinical practice. Revista Brasileira de Cirurgia Cardiovascular. 2013; 238–47. DOI: 10.5935/1678-9741.20130034
- Vianna CA, Gonzalez DA, Matijasevich A. Utilização de ácido acetilsalicílico (AAS) na prevenção de doenças cardiovasculares: um estudo de base populacional Aspirin use in cardiovascular disease prevention: a population-based study. Cad Saúde Pública. 2012; 28(6): 1122–32. DOI: 10.1590/S0102-311X2012000600011
- Smedt D De, Backer T De, Petrovic M, et al. Chronic medication intake in patients with stable coronary heart disease across Europe: Evidence from the daily clinical practice. Results from the ESC EORP European Survey of Cardiovascular Disease Prevention and Diabetes (EUROASPIRE IV) Registry. Int J Cardiol. 2020; 300: 7–13. DOI: 10.1016/j.ijcard.2019.09.015
- Barth JH, Misra S, Aakre KM, et al. Why are clinical practice guidelines not followed? The European Federation of Clinical Chemistry and Laboratory Medicine and European Union of Medical Specialists joint working group on Guidelines. Clin Chem Lab Med. 2016; 54(7): 1133–9. DOI: 10.1515/cclm-2015-0871
- Kotseva K, De Bacquer D, Jennings C, et al. Time Trends in Lifestyle, Risk Factor Control, and Use of Evidence-Based Medications in Patients With Coronary Heart Disease in Europe: Results From 3 EUROASPIRE Surveys, 1999–2013. Glob Heart. 2017; 12(4): 315–322.e3. DOI: 10.1016/j.gheart.2015.11.003
- Achelrod D, Gray A, Preiss D, Mihaylova B. Cholesterol- and blood-pressure-lowering drug use for secondary cardiovascular prevention in 2004–2013 Europe. Eur J Prev Cardiol. 2017; 24(4): 426–36. DOI: 10.1177/2047487316676906
- Oliveri R. Consenso SAC 2001. 1981; 7–8.
- Sociedade Brasileira de Cardiologia. Diretrizes SBC 2004–2008.
- Sociedade Brasileira de Cardiologia.
Diretrizes SBC 2005–2009 . Arquivos Brasileiros de Cardiologia. - Sociedade Brasileira de Cardiologia. Diretrizes SBC 2007–2011; 2011.
- Sociedade Brasileira de Cardiologia. Diretrizes da SBC 2009–2014. Soc Bras Cardiol. 2014; 728.
- Andrade MD, Macedo AVS, Piuzana ALR, et al. Diretrizes da Sociedade Brasileira de Cardiologia: Pocket Book 2013–2015. Soc Bras Cardiol. 2015; 7: 1–599.
- Kreutzer G, Directiva C, El H, et al. Consenso Prevención Cardiovascular. Rev Argent Cardiol. 2012; 80(2).
- Taddei C, Zhou B, Bixby H, et al. Repositioning of the global epicentre of non-optimal cholesterol. Nature. 2020; 582(7810): 73–7. DOI: 10.1038/s41586-020-2338-1
- Koopman C, Vaartjes I, Heintjes EM, et al. Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998–2010. Eur Heart J. 2013; 34(41): 3198–205. DOI: 10.1093/eurheartj/eht368
- Manteuffel M, Williams S, Chen W, Verbrugge RR, Pittman DG, Steinkellner A. Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J Women’s Heal. 2014; 23(2): 112–9. DOI: 10.1089/jwh.2012.3972
- Barrett E, Paige E, Welsh J, et al. Differences between men and women in the use of preventive medications following a major cardiovascular event: Australian prospective cohort study. Prev Med Reports. 2021; 22: 101342. DOI: 10.1016/j.pmedr.2021.101342
- Redfors B. Women Are Less Likely to Get Secondary Prevention Medications and Cardiac Rehabilitation. Clinical Topics. American College of Cardiology; 2017.
DOI: https://doi.org/10.5334/gh.1124 | Journal eISSN: 2211-8179
Language: English
Submitted on: Oct 8, 2021
Accepted on: May 9, 2022
Published on: Jun 8, 2022
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
© 2022 A. Marzà-Florensa, E. Drotos, P. Gulayin, D. E. Grobbee, V. Irazola, K. Klipstein-Grobusch, I. Vaartjes, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.